Fresenius Kabi France in the news

FRESUBIN PLANT BASED vanilla is a plant-based, high-calorie, high-protein medical food for individuals with nutritional needs.

A specialized range of high-calorie nutritional supplements designed for medical dietary management.

The Fresenius Kabi Fenwal site in La Châtre has regained profitability and recently hosted local business leaders for a facility tour.

Fresenius achieved 9% organic growth in late 2025, led by strong biopharma sales and medical device expansion within its Kabi division.

Fresenius Kabi received European Commission approval for its denosumab biosimilars, Conexxence and Bomyntra, following a settlement with Amgen, with a European launch expected in November 2025.

Manufacturing site in Brezins produces medical equipment for global distribution and hosted local officials to highlight its economic impact.

Guillaume Thomas from Fresenius Vial discussed medical devices and clinical nutrition with Fresenius Kabi on BFM Business.

Valérie Fontaine has been appointed as the new President of Fresenius Kabi France, bringing 30 years of internal experience to lead the subsidiary.

A leading provider of essential pharmaceutical products and medical devices for critical care and clinical nutrition focusing on innovation and sustainability.

Fresenius Kabi invested 35 million euros in a new automated production facility in Louviers to modernize its infusion bag manufacturing.

Fresenius Kabi is investing 35 million euros to automate and modernize its Louviers plant for the production of sterile infusion bags and medical devices.

Fresenius Kabi invested 35 million Euros to add two new infusion bag production lines and a new building at its Louviers facility.

Fresenius Kabi completed a €35 million investment to expand its automated production of medical infusion bags and intravenous drugs at its Louviers facility.

Fresenius Kabi is investing 710 million euros to acquire mAbxience and Ivenix, expanding its footprint in the international biosimilar and medical device markets.

Fresenius Kabi is investing 35 million euros to modernize and expand its infusion bag production plant in Louviers to meet rising demand for home care.

Fresenius Kabi is investing 35 million euros to expand production of infusion bags and medical devices at its Louviers site in France.

Eli Lilly won a patent infringement case in France against Fresenius Kabi, leading to a sales ban and significant damages for its cancer drug pemetrexed.